Status:
UNKNOWN
Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in Ph Positive ALL
Lead Sponsor:
Zhongda Hospital
Conditions:
Acute Lymphocytic Leukemia, Adult B-Cell
BCR-ABL1 Fusion Protein Expression
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
Philadelphia chromosome (BCR-ABL1, Ph) is the most common genetic abnormality in acute lymphoblastic leukemia (ALL) and an independent prognostic risk factor. With the increase of age, the incidence o...
Detailed Description
Flumatinib + hyper-CVAD (younger than 60): Induction therapy: Flumatinib 600mg per day, on an empty stomach; For cycles 1, 3, 5, and 7: cyclophosphamide (CTX) 300 mg/m² is given intravenously over 3 ...
Eligibility Criteria
Inclusion
- Diagnosed as Ph positive ALL
- Signing informed consent voluntarily
Exclusion
- Severe mental disorder
- Uncontrolled heart disease
- Be allergic to flumatinib or other research drugs
- More than 80 years old
Key Trial Info
Start Date :
March 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 30 2022
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT04375683
Start Date
March 1 2020
End Date
December 30 2022
Last Update
March 24 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University
Nanjing, Jiangsu, China, 210009
2
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University
Nanjing, Jiangsu, China, 210009